TD Cowen maintains Arcutis Biotherapeutics at Buy, raises price target to $40 from $35

TD Cowen kept its Buy rating on Arcutis Biotherapeutics and increased its price target to $40 from $35, citing a 17.5% upside from the Nov 4 close of $34.05.

Original reporting
Published Nov 5, 2026, 8:41 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 8:46 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
TD Cowen maintains Arcutis Biotherapeutics at Buy, raises price target to $40 from $35 — source image
Decision brief

The 30-second read

Low
01

Why it matters

Analyst price target increase may prompt short-term buying.

02

Market read

Analyst upgrade provides modest new information for traders.

03

What to watch

No new clinical data released; upgrade based on analyst opinion only.

Relevance 6/10Novelty 6/10Timing: today

Background

Arcutis Biotherapeutics is a clinical-stage biotech focused on dermatology.

Market effects

May boost sentiment in biotech sector.

Limited to US biotech investors.

Minimal global impact.

Counterpoint

Target raise could be premature if upcoming trial data disappoints.

Key entities

  • TD Cowen

    Equity research firm issuing the rating.

Related articles

$ARQTHighAI 8/10

Arcutis reports trial data on infant eczema treatment candidate

Arcutis Biotherapeutics (ARQT) presented INTEGUMENT-INFANT trial data for ZORYVE cream 0.05% in treating infant atopic dermatitis. The study showed no serious adverse events, with 66.7% of infants reporting itch improvement within 4 hours. The cream is approved for children 2-5 years and is under FDA review for infants 3-24 months, with a decision expected by February 23, 2027.

$ARQTMed

Arcutis (ARQT) Q3 2026 Earnings Call Transcript

Arcutis Biotherapeutics (ARQT) reported Q3 2026 revenue of $143.9M, up 45% YoY, driven by ZORYVE franchise growth. Full-year revenue guidance raised to $535M-$545M. Net income was $8.8M, with cash and securities at $259.8M. The company plans to invest in commercial initiatives for 2027 growth, focusing on dermatology and primary care.

$ARQTMedAI 8/10

TD Cowen raises Arcutis stock price target on Zoryve momentum

TD Cowen raised its price target for Arcutis Biotherapeutics (ARQT) to $40 from $35, citing strong Zoryve sales of $144M and raised 2026 guidance. Revenue grew 11% quarter-over-quarter and 45% year-over-year, with a 91% gross profit margin. The stock trades near its 52-week high at $34.05. Arcutis reported Q3 2026 revenue of $143.9M, beating estimates, but missed profit expectations.